Cite as: 566 U. S. ____ (2012)

5

Syllabus
when it is overbroad. Moreover, Congress’s equation of the two situations makes perfect sense. In either case, the brand submits misleading patent information to the FDA, delaying or blocking approval of a
generic drug that infringes no patent and thus, under the statute,
should go to market. Pp. 20–24.
601 F. 3d 1359, reversed and remanded.
KAGAN, J., delivered the opinion for a unanimous Court. SOTOMAYOR,
J., filed a concurring opinion.

